Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Titel:
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Auteur:
Kimball, Alexa B Jemec, Gregor B E Sayed, Christopher J Kirby, Joslyn S Prens, Errol Ingram, John R Garg, Amit Gottlieb, Alice B Szepietowski, Jacek C Bechara, Falk G Giamarellos-Bourboulis, Evangelos J Fujita, Hideki Rolleri, Robert Joshi, Paulatsya Dokhe, Pratiksha Muller, Edward Peterson, Luke Madden, Cynthia Bari, Muhammad Zouboulis, Christos C